AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reissued by research analysts at Kepler Capital Markets in a research report issued on Thursday, July 13th. They presently have a GBX 5,500 ($71.62) target price on the biopharmaceutical company’s stock. Kepler Capital Markets’ price objective suggests a potential upside of 24.25% from the stock’s current price.
Other analysts also recently issued reports about the company. Deutsche Bank AG restated a “buy” rating and issued a GBX 5,500 ($71.62) price objective on shares of AstraZeneca plc in a report on Wednesday, March 15th. Liberum Capital reaffirmed a “buy” rating and set a GBX 5,100 ($66.41) price target on shares of AstraZeneca plc in a research report on Tuesday, March 21st. Berenberg Bank upped their price target on shares of AstraZeneca plc from GBX 5,450 ($70.97) to GBX 5,670 ($73.84) and gave the company a “buy” rating in a research report on Monday, March 20th. Societe Generale reaffirmed a “buy” rating on shares of AstraZeneca plc in a research report on Thursday, March 23rd. Finally, Morgan Stanley reaffirmed a “buy” rating on shares of AstraZeneca plc in a research report on Monday, April 24th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the stock. AstraZeneca plc currently has an average rating of “Hold” and a consensus target price of GBX 4,932.67 ($64.24).
AstraZeneca plc (LON AZN) traded down 0.96% during trading on Thursday, reaching GBX 4384.00. The company had a trading volume of 1,583,746 shares. The stock has a 50 day moving average of GBX 4,972.77 and a 200-day moving average of GBX 4,859.70. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The company’s market capitalization is GBX 55.50 billion.
TRADEMARK VIOLATION NOTICE: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/11/astrazeneca-plc-azn-stock-rating-reaffirmed-by-kepler-capital-markets-updated-updated-updated.html.
In other AstraZeneca plc news, insider Nazneen Rahman purchased 39 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The shares were acquired at an average price of GBX 4,370 ($56.91) per share, with a total value of £1,704.30 ($2,219.43).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for AstraZeneca plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.